Leo Buckley

Why is Trump simultaneously murdering people on small boats whose identities we don’t really know (but he insists they’re drug smugglers) while also freeing people we *know* are guilty of drug crimes?

REDHART2 is a simple study - hospitalized for HFrEF --> CPET within 2 weeks of discharge, treatment with anakinra (or placebo, 2:1) for 6 months, CPET repeated at 6, 12, and 24 weeks. Four visits in 6 months all at VCU. Reach out to me or @bvantassell with questions.

Interleukin-1 in recently decompensated heart failure- REDHART2 study- in the last phase of enrollment @VCUHealthHeart @VCUHealth clinicaltrials.gov/ct2/show/NCT03… -Reach out with referrals/questions. @bvantassell @VCUPharmacy @VCUDPOSChair @CardioUva @UVACVRC

Antonio Abbate, MD & Ben Van Tassell, PharmD - Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3) (VCU-ART3) @AbbateAntonio @bvantassell #VCUART3Trial #MyocardialInfarction #Cardiology #Research cardiologytalk.com/video/634/anto…

Journal publication is a multi-billion industry… and this article estimates that academics donate at least $1.5b annually in labor to support the current enterprise. Write papers, donate reviews, often pay for publication. What a model. …rchintegrityjournal.biomedcentral.com/articles/10.11… HT @atulbutte

We received feedback on our latest set of faculty surveys but don’t believe it is representative of the faculty because of what we have been told in private meetings. Thanks for participating!

Are the NLRP3 inflammasome and interleukin 1-beta potentially novel therapeutic targets for the treatment of #pericarditis? Find out in this new issue of #JACCBTS: bit.ly/3pGKglm #CardioImmunology

Solid team work @VCUHealthHeart - ask me how to join this research team

STAT request: 2021 MeRIT Scholarship Applications due today February 8 at 8pm EST. Receive $3,000 to develop expertise in investigator-initiated research over a 2-year program. Contact lfbuckley@bwh.harvard.edu (@lfbpharmd ) for questions

The novel program led by pharmacists is a model for remote healthcare delivery to reduce inequities and improve QOC. ms.spr.ly/6012pyHqj #AHA20

Proud to have been part of RHAPSODY at @VCUHealthHeart @VCU_CCTR Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis | NEJM nejm.org/doi/full/10.10…

Thank so much @DLKirkman @vcukhs @kim_youngdeok #AHA20

This month we kickoff with a new section “Emerging Concepts in Pharmacotherapeutics”, edited by @DaveDixonPharmD   #pharmacology #cardiovascular #clinical #bempedoic #hyperlipidemia #drugs #prescriptions

After sitting in study section last week reviewing proposals for K-series career development awards, thought I'd list my top 5 reasons why such proposals fail. (Not linked to any one submission.) Junior scientists who might be interested in applying - avoid these pitfalls!!

Remote, algorithm-driven, navigator-administered medication optimization enhanced utilization and dose titration of neurohormonal antagonists versus usual care in HFrEF. This approach may represent a novel strategy to address underutilization of GDMT ja.ma/3c88GPI

Medicaid Expansion & Antihyperglycemic Therapies in @ADA_Journals by @adsumarsono, @sara_rm84, & colleagues. Low-income adults carry a disproportionate burden of CV disease. Improving insurance coverage represents a key determinant of therapeutic access. care.diabetesjournals.org/content/early/…

I am excited to share our editorial just published on @JACCJournals where we discuss the role of nutrition in the management of heart failure, beyond dietary sodium restriction. @vcukhs @VCUCHS @VCUnews heartfailure.onlinejacc.org/content/8/9/765

COPS trial: in a small RCT, colchicine did not improve a composite of death or CV outcomes at 12 mos post ACS. Small # of events. Adverse non-CV mortality signal (5 vs 0 favoring placebo) 🤷🏽‍♂️ @UTSWIMchief @UTSWCardfellow ahajournals.org/doi/pdf/10.116…

VCUART3 study showed promising benefits of IL-1 blockade with anakinra in STEMI. ahajournals.org/doi/10.1161/JA… Looking for other centers in the USA for a phase II trial with a novel IL-1 blocker (contact me antonio.abbate@vcuhealth.org if interested)

Nice summary and overview of cytokines in COVID-19 -- thanks to Leo Buckley, PharmD @lfbpharmd for leading this effort. bit.ly/3iB78zp